Long-Term Tirzepatide Use: What 72-Week Data Really Tells Us

What the SURMOUNT Trials Actually Showed About Long-Term Use

The SURMOUNT trial program represents the most comprehensive long-term dataset for tirzepatide in weight management. Understanding what these trials demonstrated, and equally important, what they did not study, is essential for patients and providers making decisions about extended treatment.

SURMOUNT-1, the pivotal trial, followed 2,539 adults with obesity or overweight for 72 weeks (approximately 18 months). Participants received tirzepatide at doses of 5 mg, 10 mg, or 15 mg alongside lifestyle intervention. At 72 weeks, average body weight reductions were 15.0%, 19.5%, and 20.9% for the three dose levels respectively, compared to 3.1% for placebo. The highest dose group saw 36.2% of participants achieving 25% or greater body weight loss, a threshold rarely reached with any prior pharmaceutical intervention.

Crucially, weight loss in SURMOUNT-1 followed a progressive trajectory that did not plateau until approximately weeks 60-72, suggesting that the medication's effectiveness was sustained throughout the entire study period without any evidence of tolerance or reduced efficacy. This is a meaningful finding: many previous obesity medications showed declining effectiveness over time, but tirzepatide maintained its weight-lowering effect continuously over 18 months. For a comparison with semaglutide trial results, see our guide on tirzepatide vs semaglutide.

SURMOUNT-2, which studied tirzepatide specifically in patients with type 2 diabetes and obesity, provided additional long-term safety and efficacy data. These patients, who often have more complex metabolic profiles, showed sustained weight loss and significant improvements in glycemic control through the full study duration. The consistency of results across different patient populations strengthens confidence in long-term use.

Weight Maintenance on Continued Treatment

One of the most important questions for long-term use is whether weight loss is maintained with continued treatment or whether the body eventually overcomes the medication's effects. The available evidence strongly supports sustained maintenance.

After the initial weight loss phase (typically 12-18 months), patients who continue tirzepatide enter a maintenance phase where weight stabilizes at the new lower level. This plateau is not a sign of the medication "stopping working" but rather represents a new equilibrium between the medication's appetite-suppressing and metabolic effects and the body's compensatory mechanisms. At this maintenance level, the medication continues to actively prevent weight regain.

Real-world data from early prescribing experience supports the trial findings. Patients who maintain consistent treatment with tirzepatide beyond 12 months generally sustain their weight loss, and some continue to lose additional weight in the second year, particularly if they intensify lifestyle efforts or optimize their dose during this period. This is an encouraging signal for patients considering whether long-term treatment is worthwhile.

The concept of treating obesity as a chronic disease, similar to hypertension or type 2 diabetes, is central to understanding the role of long-term tirzepatide use. Just as blood pressure medications maintain their effect as long as they are taken and blood pressure rises when they are stopped, weight management medications maintain weight loss during active treatment and weight regain occurs upon discontinuation. This paradigm shift away from short-term "diet drug" thinking toward chronic disease management is supported by every major medical society and obesity medicine guideline. For more on this topic, see our article on real-world GLP-1 effectiveness.

Side Effect Evolution Over Time

The trajectory of side effects over the course of long-term tirzepatide treatment is one of the most reassuring aspects of the available data. The side effect profile does not worsen over time; in fact, the most common adverse effects improve significantly with continued use.

Importantly, the 72-week trial data showed no increased incidence of serious adverse events with prolonged treatment. Pancreatitis rates were not elevated compared to placebo. Gallbladder events, while slightly more common than placebo (as is typical with rapid weight loss from any cause), did not increase in frequency with treatment duration. Thyroid C-cell concerns, which are monitored as a class effect of GLP-1 receptor agonists, showed no increased signals in the human clinical data through 72 weeks. For guidance on managing early side effects, see our tirzepatide first month guide.

Dose Adjustments Over Time: Finding the Maintenance Sweet Spot

Long-term tirzepatide use does not necessarily mean staying on the highest dose indefinitely. Many patients and providers explore dose adjustment strategies once the initial weight loss goal has been achieved, seeking to find the lowest effective dose that maintains results while minimizing side effects and cost.

The standard dose escalation for tirzepatide begins at 2.5 mg weekly and increases every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. Not all patients require the maximum dose to achieve meaningful weight loss. Clinical experience suggests that some patients achieve excellent results at 10 mg or even 7.5 mg, and dose reduction from the maximum is sometimes possible during the maintenance phase without significant weight regain.

The approach to dose reduction should be gradual and data-driven. After a patient has maintained stable weight for at least 3-6 months at a given dose, a stepwise reduction of one dose level (e.g., from 15 mg to 12.5 mg, or from 10 mg to 7.5 mg) can be tried with close monitoring. If weight remains stable after 8-12 weeks at the lower dose, the reduction has been successful. If weight begins to trend upward, returning to the previous dose is straightforward.

Some patients find that their maintenance dose is lower than their maximum tolerated dose, which offers benefits in terms of reduced side effects and potentially lower medication cost. Others require the full dose for sustained maintenance and find that any reduction triggers weight regain. The only way to determine the optimal long-term dose for a specific patient is through careful, supervised dose adjustment. For detailed dosing information, explore our tirzepatide maintenance dose guide.

Discontinuation Data: What SURMOUNT-4 Revealed

SURMOUNT-4 is the most important study for understanding what happens when tirzepatide is stopped. This trial used a unique design: all participants received tirzepatide for 36 weeks and lost an average of approximately 20% of their body weight. They were then randomized to either continue tirzepatide or switch to placebo for an additional 52 weeks. The results were stark and informative.

The pattern of regain in the placebo group followed a predictable trajectory. Weight began increasing within the first month of discontinuation, with the steepest regain occurring in the first 3-6 months. By 12 months post-discontinuation, participants had regained approximately two-thirds of the weight they had lost during the initial treatment phase. Importantly, the regain was not instantaneous or catastrophic, but it was persistent and progressive.

Several factors are believed to drive post-discontinuation weight regain. Appetite returns to pre-treatment levels as GLP-1 and GIP receptor stimulation ceases. Metabolic rate, which decreases during weight loss as part of the body's energy conservation response, does not immediately recover. Hormonal changes, including increases in ghrelin (the hunger hormone) and decreases in satiety hormones, contribute to increased food intake. These biological forces make sustained weight loss without ongoing pharmacological support extremely difficult for most patients.

The SURMOUNT-4 data has been instrumental in shifting the clinical and policy discussion around obesity treatment toward a chronic disease management model. It demonstrates that tirzepatide is not a short-term intervention but a long-term treatment that provides ongoing benefit as long as it is maintained. For strategies to prevent weight regain, see our article on weight regain prevention on GLP-1 medications.

Cardiovascular Long-Term Benefits

The cardiovascular implications of long-term tirzepatide use extend well beyond weight loss. The SURMOUNT trials documented consistent improvements in multiple cardiovascular risk factors throughout the treatment period, and these improvements provide strong indirect evidence for long-term cardiovascular benefit.

Blood pressure reductions on tirzepatide have been clinically significant, with average systolic blood pressure decreases of 6-8 mmHg observed in the SURMOUNT trials. These reductions are sustained with continued treatment and are partly independent of weight loss, suggesting direct vascular benefits of tirzepatide beyond what would be expected from weight reduction alone. For patients with hypertension, this can translate into reduced need for antihypertensive medications over time.

Lipid profile improvements are another consistent finding. Total cholesterol, LDL cholesterol, and triglycerides decrease significantly during tirzepatide treatment, while HDL cholesterol tends to increase. These changes improve the overall atherogenic lipid profile and reduce calculated cardiovascular risk. The lipid improvements are maintained with continued treatment and reverse partially upon discontinuation, further supporting the case for ongoing therapy.

The ongoing SURPASS-CVOT (Cardiovascular Outcomes Trial) will provide definitive data on whether tirzepatide reduces the incidence of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or high cardiovascular risk. Based on the robust surrogate marker improvements observed in existing trials and the positive CVOT data for the related GLP-1 agonist semaglutide (SELECT trial), there is strong scientific rationale to expect positive cardiovascular outcomes for tirzepatide as well. For information on the broader health effects, see our article on GLP-1 health benefits beyond weight loss.

Looking Ahead: 5-Year Data and Beyond

While the current evidence base for tirzepatide long-term use is robust through 72 weeks, the obesity medicine field is eagerly awaiting longer-duration data. Several ongoing studies and registries will provide critical information about tirzepatide use over 3-5+ year time horizons.

The SURPASS-CVOT trial, expected to provide results within the next 1-2 years, will offer 4-5 year safety and efficacy data in a large patient population. Post-marketing surveillance programs continue to collect real-world safety data on an ongoing basis, with millions of patient-treatment-months now accumulated since the medication's launch. These data sources will progressively strengthen confidence in the long-term safety profile.

From a practical standpoint, patients considering long-term tirzepatide use should understand that while the current data is highly reassuring through 18 months and real-world experience extends beyond 2 years, very long-term data (5-10 years) does not yet exist for this specific molecule. However, the GLP-1 receptor agonist class as a whole has a safety track record extending over 15 years (starting with exenatide and liraglutide), and no unexpected long-term safety signals have emerged for the class during this period.

The decision to pursue long-term treatment should be made collaboratively between patient and provider, weighing the demonstrated benefits (sustained weight loss, metabolic improvements, probable cardiovascular protection) against the costs, the commitment to ongoing injections, and the current limits of ultra-long-term data. For most patients with obesity, the evidence strongly favors continued treatment as long as the medication is well-tolerated and effective. Learn more about long-term treatment planning in our long-term metabolic benefits of GLP-1 article.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). N Engl J Med. 2023;389(24):2221-2232.
5. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.
6. Fruhbeck G, et al. Obesity: the gateway to ill health. Lancet Diabetes Endocrinol. 2023;11(3):167-169.